In fact, treatment strategies aimed at decreasing TNFα resulted in decreased angiogenic IL-8 production in vitro and decreased serum levels of angiogenic VEGF in RA patients [66,67]. This evidence concerns the gene CXCL8 and rheumatoid arthritis.